Transfection of hPSC-Cardiomyocytes Using Viafect™ Transfection Reagent.

ABSTRACT: Twenty years since their first derivation, human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) have shown promise in disease modelling research, while their potential for cardiac repair is being investigated. However, low transfection efficiency is a barrier to wider realisation of the potential this model system has to offer. We endeavoured to produce a protocol for improved transfection of hPSC-CMs using the Viafect^TM reagent by Promega. Through optimisation of four essential parameters: (i) serum supplementation, (ii) time between replating and transfection, (iii) reagent to DNA ratio and (iv) cell density, we were able to successfully transfect hPSC-CMs to ~95% efficiencies. Transfected hPSC-CMs retained high purity and structural integrity despite a mild reduction

SUBMITTER: Bodbin SE 

PROVIDER: S-EPMC7564709 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature